ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiology of Community Acquired Pneumonia in North Israel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00390819
Recruitment Status : Unknown
Verified October 2006 by HaEmek Medical Center, Israel.
Recruitment status was:  Not yet recruiting
First Posted : October 20, 2006
Last Update Posted : October 20, 2006
Sponsor:
Information provided by:
HaEmek Medical Center, Israel

Brief Summary:

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality and is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

Aim of study: To identify common pathogens causing CAP in hospitalized patients in north Israel.


Condition or disease
Community Acquired Pneumonia

Detailed Description:

Pneumonia in general and CAP in particular is considered as one of the most common bacterial infections, associated with high rates of morbidity and mortality.

CAP is highly significant economically since all respiratory infections, and pneumonia especially, cause about 80% of antimicrobials use in the community. The high frequency of respiratory infections and the excessive use of antimicrobials are major contributors to the development of pathogens resistant to antimicrobials. In addition, in CAP almost all patients are treated empirically, without identification of causing pathogen.

CAP is divided to two principal groups: Bacterial CAP and Atypical CAP. Since pathogens are different, treatment approach is also different. The main obstacle is absence of adequate diagnostic immediate and cheap tools to enable identifying pathogen and hence treatment is not always appropriate. Giving the right therapy at the right time is of major importance since early start of correct treatment is linked to morbidity and mortality of patients. For prescribing appropriate empiric therapy, knowing the epidemiology of CAP, i.e. the frequent causing pathogens according to age groups and other demographic characteristics, is essential.

Unfortunately, except one study conducted 10 years ago by Dr. Liberman from Soroka Medical Center, there is no characteristic information regarding causing pathogens. Lacking this data, might result in selecting inadequate treatment.

Material & Methods:

We should enroll about 300 patients hospitalized in Ha'Emek Medical Center with the diagnosis of CAP, in order to make the study results statistically significant.

In addition to demographic and clinical data, following tests will be performed:

  1. Blood cultures
  2. Sputum
  3. PCR - throat culture to the following pathogens:

    • Mycoplasma pneumoniae
    • Chlamydia pneumoniae
    • Legionella
    • Adenovirus
    • Influenza A
    • Influenza B
    • RSV
    • Metapneumovirus
    • Parainfluenza
    • Pneumococcal antigen in urine

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Epidemiology of Community Acquired Pneumonia in North Israel
Study Start Date : November 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Community acquired pneumonia
  • Hospitalization

Exclusion Criteria:

  • Immunocompromised patients
  • Patients under chemotherapy treatment
  • Patients under steroids treament

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00390819


Contacts
Contact: Fahmi Shibli, M.D. 972-4-6494000 ext 4347 fahmi_shibli@yahoo.ie

Locations
Israel
Ha'Emek Medical Center Not yet recruiting
Afula, Israel, 18101
Contact: Fahmi Shibli, M.D.    972-4-6494000 ext 4347    fahmi_shibli@yahoo.ie   
Sub-Investigator: Raul Raz, M.D.         
Sub-Investigator: Raul Colodner, PhD         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: Fahmi Shibli, M.D. Ha'Emek Medical Center, Afula, Israel

Publications:
ClinicalTrials.gov Identifier: NCT00390819     History of Changes
Other Study ID Numbers: 131074
First Posted: October 20, 2006    Key Record Dates
Last Update Posted: October 20, 2006
Last Verified: October 2006

Keywords provided by HaEmek Medical Center, Israel:
Community acquired pneumonia

Additional relevant MeSH terms:
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections